Apolipoprotein CIII bound to apoB-containing lipoproteins is associated with small, dense LDL independent of plasma triglyceride levels in healthy men

Atherosclerosis

Volumn 211, Issue 1, 2010, Pages 337-341

  Shin, Min Jeong ^a,b   Krauss, Ronald M ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^b Korea University   (South Korea)

Author keywords

Apolipoprotein CIII; Atherogenic lipoprotein phenotype; Coronary heart disease; Small dense LDL

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; BODY MASS; DENSITY GRADIENT CENTRIFUGATION; GROUPS BY AGE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; MULTIPLE REGRESSION; NORMAL HUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN BINDING; TRIACYLGLYCEROL BLOOD LEVEL; ULTRACENTRIFUGATION; BLOOD; CARDIOVASCULAR DISEASES; MIDDLE AGED; RISK;

APOLIPOPROTEIN C-III; APOLIPOPROTEINS B; CARDIOVASCULAR DISEASES; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; RISK; TRIGLYCERIDES; ULTRACENTRIFUGATION;

EID: 77954246799     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.02.025     Document Type: Article

References (35)

1. Gerber Y., Goldbourt U., Segev S., Harats D. Indices related to apo CII and CIII serum concentrations and coronary heart disease: a case-control study. Prev Med 2003, 37:18-22.
2. Chivot L., Mainard F., Bigot E., et al. Logistic discriminant analysis of lipids and apolipoproteins in a population of coronary bypass patients and the significance of apolipoproteins C-III and E. Atherosclerosis 1990, 82:205-211.
3. Sacks F.M., Alaupovic P., Moye L.A., et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 2000, 102:1886-1892.
4. Alaupovic P., Mack W.J., Knight-Gibson C., Hodis H.N. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by a sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol 1997, 17:715-722.
5. Hodis H.N., Mack W.J., Azen S.P., et al. Triglyceride and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by a quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994, 90:42-49.
6. Pollin T.I., Damcott C.M., Shen H., et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 2008, 322:1702-1705.
7. Ginsberg H.N., Le N.A., Goldberg I.J., et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceriderich lipoproteins by lipoprotein lipase in vivo. J Clin Invest 1986, 78:1287-1295.
8. Brown W.V., Baginsky M.L. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochem Biophys Res Commun 1972, 46:375-382.
9. Wang C.S., McConathy W.J., Kloer H.U., Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest 1985, 75:384-390.
10. Sehayek E., Eisenberg S. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceriderich lipoproteins through the low density lipoprotein receptor pathway. J Biol Chem 1991, 266:18259-18267.
11. Clavey V., Lestavel-Delattre S., Copin C., Bard J.M., Fruchart J.C. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. Arterioscler Thromb Vasc Biol 1995, 15:963-971.
12. Kawakami A., Osaka M., Aikawa M., et al. Toll-Like receptor 2 mediates apolipoprotein CIII-induced monocyte activation. Circ Res 2008, 103:1402-1409.
13. Chan D.C., Watts G.F., Nguyen M.N., Barrett P.H.R. Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein b-100 kinetics. Arterioscler Thromb Vasc Biol 2006, 26:590-596.
14. Campos H., Perlov D., Khoo C., Sacks F.M. Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia. J Lipid Res 2001, 42:1239-1249.
15. Berneis K.K., Krauss R.M. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 2002, 43:1363-1379.
16. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
17. Krauss R.M., Blanche P.J., Rawlings R.S., Fernstrom H.S., Williams P.T. Separate effects of reduced carbohydrate intake and weight loss on atherogenic dyslipidemia. Am J Clin Nutr 2006, 83:1025-1031.
18. Krauss R.M., Blanche P.J. Detection and quantitation of LDL subfractions. Curr Opin Lipidol 1992, 3:377-383.
19. Stampfer M.J., Krauss R.M., Ma J., et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996, 276:882-888.
20. St-Pierre A.C., Cantin B., Dagenais G.R., et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 2005, 25:553-555.
21. Sundaram M., Links P., Khalil M.B., Zhong S., Yao Z. New insights into the roles of apolipoprotein C-III in stimulating the production of hepatic VLDL. Arterioscler Thromb Vasc Biol 2007, 27:e62.
22. Chan D.C., Watts G.F., Redgrave T.G., Mori T.A., Barrett P.H.R. Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration. Metab Clin Exp 2002, 51:1041-1046.
23. Jong M.C., Hofker M.H., Havekes L.M. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol 1999, 19:472-484.
24. Batal R., Tremblay M., Barrett P.H.R., et al. Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects. J Lipid Res 2000, 41:706-718.
25. Quarfordt S.H., Michalopoulos G., Schirmer B. The effect of human C apolipoproteins on the in vitro hepatic metabolism of triglyceride emulsions in the rat. J Biol Chem 1982, 257:14642-14647.
26. Davidsson P., Hulthe J., Fagerberg B., et al. A proteomic study of the apolipoproteins in LDL subclasses in patients with the metabolic syndrome and type 2 diabetes. J Lipid Res 2005, 46:1999-2006.
27. Mauger J.F., Couture P., Bergeron N., Lamarche B. Apolipoprotein C-III isoforms: kinetics and relative implication in lipid metabolism. J Lipid Res 2006, 47:1212-1218.
28. Scheffer P.G., Teerlink T., Dekker J.M., et al. Increased plasma apolipoprotein C-III concentration independently predicts cardiovascular mortality: The Hoorn Study. Clin Chem 2008, 54:1325-1330.
29. Olivieri O, Martinelli N, Girelli D, et al. Apolipoprotein C-III predicts cardiovascular mortality in severe coronary artery disease and is associated with an enhanced plasma thrombin generation. J Thromb Hemostasis; in press.
30. Zheng C., Khoo C., Ikewaki K., Sacks F.M. Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions. J Lipid Res 2007, 48:1190-1203.
31. Kawakami A., Aikawa M., Alcaide P., et al. Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation 2006, 114:681-687.
32. Kawakami A., Osaka M., Tani M., et al. Apolipoprotein CIII links hyperlipidemia with vascular endothelial cell dysfunction. Circulation 2008, 118:731-742.
33. Olin-Lewis K., Krauss R.M., La Belle M., et al. ApoC-III content of apoB-containing lipoproteins is associated with binding to the vascular proteoglycan biglycan. J Lipid Res 2002, 43:1969-1977.
34. Hiukka A., Ståhlman M., Pettersson C., et al. ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan. Diabetes 2009, 58:2018-2026.
35. Williams P.T., Superko H.R., Haskell W.L., et al. Smallest LDL particles are most strongly related to coronary disease progression in men. Arterioscler Thromb Vasc Biol 2003, 23:314-321.